• Japanese
  • Korean
  • Chinese
Cover Image

Oncology Partnering Terms and Agreements

The Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies.

Key benefits

Oncology Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of oncology deal trends since 2007
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to over 4,000 actual oncology contracts entered into by the world's biopharma companies
  • Detailed access to actual oncology contracts enter into by the leading fifty bigpharma companies
  • Insight into the terms included in a oncology agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Oncology Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to oncology trends and structure of deals entered into by leading companies worldwide.

Oncology Partnering Terms and Agreements includes:

  • Trends in oncology dealmaking in the biopharma industry since 2007
  • Analysis of oncology deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life oncology deals
  • Access to oncology contract documents
  • The leading oncology deals by value since 2007
  • Most active oncology dealmakers since 2007
  • The leading oncology partnering resources

In Oncology Partnering Terms and Agreements, the available contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Oncology Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 4,000 oncology deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise oncology rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Welcome to the Oncology Partnering Terms and Agreements report.

The report provides a detailed understanding and analysis of how and why companies enter oncology partnering deals. The majority of deals are discovery, preclinical or development stage whereby the licensee obtains a right or an option right to license the licensors oncology technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest oncology deals and contracts announced in the healthcare sectors.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The report includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates.

This report contains a comprehensive listing of all oncology partnering deals announced since 2007 including financial terms where available, including over 4000 links to online deal records of actual oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of oncology dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in oncology dealmaking since 2007 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading oncology deals since 2007. Deals are listed by headline value, signed by bigpharma, big biotech and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of oncology deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of oncology deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all oncology partnering deals signed and announced since 2007. The chapter is organized by oncology deal type, stage of development and technology type focus. Each deal title links via Weblink to an online version of the deal record with the contract document.

Chapter 7 provides a comprehensive directory of all oncology partnering deals signed and announced since 2007. The chapter is organized by specific oncology therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all oncology partnering deals signed and announced since 2007. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in oncology partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of oncology technologies and products.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in oncology dealmaking

  • 2.1. Introduction
  • 2.2. Oncology partnering over the years
  • 2.3. Bigpharma oncology dealmaking activity
  • 2.4. Bigpharma not active in oncology
  • 2.5. Oncology partnering by deal type
  • 2.6. Oncology partnering by industry sector
  • 2.7. Oncology partnering by stage of development
  • 2.8. Oncology partnering by technology type
  • 2.9. Oncology partnering by oncology indication
  • 2.10. Average deal terms for oncology
    • 2.10.1. Oncology headline values
    • 2.10.2. Oncology upfront payments
    • 2.10.3. Oncology milestone payments
    • 2.10.4. Oncology royalty rates

Chapter 3 - Leading oncology deals

  • 3.1. Introduction
  • 3.2. Top oncology deals by value
  • 3.3. Top oncology deals involving bigpharma

Chapter 4 - Bigpharma oncology deals

4.1. Introduction 4.2. How to use bigpharma partnering deals

  • 4.3. Bigpharma oncology partnering company profiles
    • Abbott
    • Actavis
    • Actelion
    • Allergan
    • Amgen
    • Aspen Pharmacare
    • Astellas
    • AstraZeneca
    • Baxter International
    • Bayer
    • Biogen Idec
    • Boehringer Ingelheim
    • Bristol-Myers Squibb
    • Celgene
    • CSL
    • Daiichi Sankyo
    • Dainippon Sumitomo
    • Eisai
    • Eli Lilly
    • Endo Pharmaceuticals
    • Galderma
    • Gilead Sciences
    • GlaxoSmithKline
    • Grifols
    • Hospira
    • Johnson & Johnson
    • Kyowa Hakko Kirin
    • Lundbeck
    • Menarini
    • Merck & Co
    • Merck KGaA
    • Mitsubishi Tanabe
    • Novartis
    • Novo Nordisk
    • Otsuka
    • Pfizer
    • Purdue
    • Roche
    • Sanofi
    • Servier
    • Takeda
    • Teva
    • Valeant
    • Watson

Chapter 5 - Oncology partnering contracts directory

  • 5.1. Introduction
  • 5.2. By deal type
    • Asset purchase
    • Assignment
    • Bigpharma outlicensing
    • Co-development
    • Collaborative R&D
    • Co-market
    • Contract service
    • Co-promotion
    • CRADA
    • Cross-licensing
    • Development
    • Distribution
    • Equity purchase
    • Evaluation
    • Grant
    • Joint venture
    • Licensing
    • Litigation
    • Loan
    • Manufacturing
    • Marketing
    • Material transfer
    • Option
    • Promotion
    • Research
    • Royalty financing
    • Settlement
    • Spin out
    • Sub-license
    • Supply
    • Technology transfer
    • Termination
    • Warranty
  • 5.3. By stage of development
    • Discovery
    • Preclinical
    • Phase I
    • Phase II
    • Phase III
    • Regulatory
    • Marketed
    • Formulation
  • 5.4. By technology type
    • Analysis
    • Animal models
    • Antibodies
    • Assays
    • Bioinformatics
    • Biological compounds
    • Biomarkers
    • Cell therapy
    • Clinical testing
    • Diagnostic - companion
    • Devices
    • Diagnostics
    • Discovery tools
    • Drug delivery
    • Enabling technology
    • Enviromental
    • Epigenetics
    • Equipment
    • Facilities
    • Gene therapy
    • Genomics
    • Imaging
    • Implant
    • Industrial chemicals
    • In vitro models
    • Nanotechnology
    • Natural product
    • Oligonucleotide
    • Orphan drug
    • Peptides
    • Personalised medicine
    • Pharmacogenomics
    • Processes
    • Proteomics
    • Radio/Chemo-therapy
    • Recombinant DNA
    • Research services
    • Research supplies
    • RNA therapeutics
    • Screening
    • Small molecules
    • Software tools
    • Stem cells
    • Vaccines

Chapter 6 - Oncology dealmaking by indication

  • 6.1. Introduction
  • 6.2. Deals by therapeutic indication
    • Oncology
    • Adenocarcinoma
    • Basal cell carcinoma
    • Bile duct cancer
    • Bladder cancer
    • Bone cancer
    • Brain cancer
    • Breast cancer
    • Cervical cancer
    • Colorectal cancer
    • Endometrial
    • Esophageal cancer
    • Gastric cancer
    • Head and neck cancer
    • Kaposi's sarcoma
    • Kidney cancer
    • Leukemia
    • Acute lymphoblastic leukemia
    • Acute myelogenous leukemia
    • Chronic lymphocytic leukemia
    • Chronic myelogenous leukemia
    • Liver cancer
    • Lung cancer
    • Non small cell lung cancer
    • Small cell lung cancer
    • Lymphoma
    • Hodgkin's lymphoma
    • Non Hodgkin's lymphoma
    • Melanoma
    • Mesothelioma
    • Metastases
    • Bone metastases
    • Multiple myeloma
    • Neuroblastoma
    • Ovarian cancer
    • Pancreatic cancer
    • Prostate cancer
    • Renal cell carcinoma
    • Sarcoma
    • Non-melanoma skin cancer
    • Solid tumors
    • Symptoms
    • Alopecia
    • Cachexia
    • Cancer pain
    • Neuropathic
    • Chemotherapy
    • Dysphagia
    • Lymphoedema
    • Nausea
    • Oral mucositis
    • Radiotherapy
    • Vomiting
    • Testicular cancer
    • Thyroid cancer

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

About Wildwood Ventures

  • Current Partnering
  • Current Agreements

Recent titles from CurrentPartnering

Order Form - Reports

Order Form - Therapy Reports

Appendices

  • Appendix 1 - Directory of oncology deals by company A-Z 2009-2014
  • Appendix 2 - Directory of oncology deals by deal type 2007-20123
  • Appendix 3 - Directory of oncology deals by stage of development 2009-2014
  • Appendix 4 - Directory of oncology deals by technology type 2009-2014
  • Appendix 5 - Deal type definitions

Table of figures

  • Figure 1: Oncology partnering since 2009
  • Figure 2: Bigpharma - top 50 - Oncology deals 2009 to 2014
  • Figure 3: Bigpharma oncology deal frequency - 2009 to 2014
  • Figure 4: Inactive bigpharma in oncology 2009-2014
  • Figure 5: Oncology partnering by deal type since 2009
  • Figure 6: Oncology partnering by industry sector since 2009
  • Figure 7: Oncology partnering by stage of development since 2009
  • Figure 8: Oncology partnering by technology type since 2009
  • Figure 9: Oncology partnering by oncology target since 2009
  • Figure 10: Oncology deals with a headline value
  • Figure 11: Oncology deal headline value distribution, US$million - discovery stage
  • Figure 12: Oncology deal headline value distribution, US$million - preclinical stage
  • Figure 13: Oncology deal headline value distribution, US$million - phase I stage
  • Figure 14: Oncology deal headline value distribution, US$million - phase II stage
  • Figure 15: Oncology deal headline value distribution, US$million - phase III stage
  • Figure 16: Oncology deal headline value distribution, US$million - regulatory stage
  • Figure 17: Oncology deal headline value distribution, US$million - marketed stage
  • Figure 18: Summary median headline value by stage of development, 2009-2014
  • Figure 19: Oncology deals with upfront payment values
  • Figure 20: Oncology deal upfront payment distribution, US$million - discovery stage
  • Figure 21: Oncology deal upfront payment distribution, US$million - preclinical stage
  • Figure 22: Oncology deal upfront payment distribution, US$million - phase I stage
  • Figure 23: Oncology deal upfront payment distribution, US$million - phase II stage
  • Figure 24: Oncology deal upfront payment distribution, US$million - phase III stage
  • Figure 25: Oncology deal upfront payment distribution, US$million - regulatory stage
  • Figure 26: Oncology deal upfront payment distribution, US$million - marketed stage
  • Figure 27: Summary median upfront payments by stage of development, 2009-2014
  • Figure 28: Oncology deals with milestone payments
  • Figure 29: Oncology deal milestone distribution, US$million - discovery stage
  • Figure 30: Oncology deal milestone distribution, US$million - preclinical stage
  • Figure 31: Oncology deal milestone distribution, US$million - phase I stage
  • Figure 32: Oncology deal milestone distribution, US$million - phase II stage
  • Figure 33: Oncology deal milestone distribution, US$million - phase III stage
  • Figure 34: Oncology deal milestone distribution, US$million - regulatory stage
  • Figure 35: Oncology deal milestone distribution, US$million - marketed stage
  • Figure 36: Oncology deals with royalty rates, %
  • Figure 37: Oncology deal royalty rate distribution, US$million - discovery stage
  • Figure 38: Oncology deal royalty rate distribution, US$million - preclinical stage
  • Figure 39: Oncology deal royalty rate distribution, US$million - phase I stage
  • Figure 40: Oncology deal royalty rate distribution, US$million - phase II stage
  • Figure 41: Oncology deal royalty rate distribution, US$million - phase III stage
  • Figure 42: Oncology deal royalty rate distribution, US$million - regulatory stage
  • Figure 44: Summary median royalty rate by stage of development, 2009-2014
  • Figure 45: Top oncology deals by value since 2009
  • Figure 46: Top oncology deals signed by bigpharma value since 2009
  • Figure 47: Online partnering resources
  • Figure 48: Forthcoming partnering events
Show More
Pricing
Get Notified
Email me when related reports are published